Daniel Mufson

USPTO Granted Patents = 11 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4

Average Co-Inventor Count = 6.6

ph-index = 10

Forward Citations = 398(Granted Patents)

Company Filing History:

9 out of 114

Alexza Pharmaceuticals, Inc.

patents

1 out of 22

Alexza Molecular Delivery Corporation

Years Active: 2004-2021

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11065400 - Aerosol forming device for use in inhalation therapy (2021-07-20),

2. 9687487 - Aerosol forming device for use in inhalation therapy (2017-06-27),

3. 9636254 - Systems for reducing pressure in an organ (2017-05-02),

4. 9439907 - Method of forming an aerosol for inhalation delivery (2016-09-13),

5. 9308208 - Aerosol generating method and device (2016-04-12),

6. 8955512 - Method of forming an aerosol for inhalation delivery (2015-02-17),

7. 8074644 - Method of forming an aerosol for inhalation delivery (2011-12-13),

8. 7942147 - Aerosol forming device for use in inhalation therapy (2011-05-17),

9. 7766013 - Aerosol generating method and device (2010-08-03),

10. 7537009 - Method of forming an aerosol for inhalation delivery (2009-05-26),

11. 6682716 - Delivery of aerosols containing small particles through an inhalation route (2004-01-27),

Title: The Innovations of Daniel Mufson

Introduction

Daniel Mufson is a prominent inventor based in Napa, California, known for his significant contributions to inhalation therapy technologies. With a total of 11 patents to his name, his work is instrumental in advancing medical devices that enhance the delivery of therapeutic aerosols.

Latest Patents

Mufson's latest innovations include devices specifically designed for inhalation therapy. Notably, he has developed an aerosol forming device that enables the inhalation delivery of aerosols containing small particles. This device features a housing along with an airway that incorporates a gas/vapor mixing airway, ensuring effective drug delivery. A subassembly within the airway consists of a metallic substrate coated with a drug-containing composition, contributing to the efficiency of inhalation therapy.

Career Highlights

Throughout his career, Daniel Mufson has been affiliated with several esteemed organizations, including Alexza Pharmaceuticals, Inc. and Alexza Molecular Delivery Corporation. His efforts in these companies have led to the development of groundbreaking technologies that support respiratory health.

Collaborations

Mufson's accomplishments are further bolstered by his collaborations with notable colleagues such as Craig C. Hodges and Peter Lloyd. These partnerships have played a vital role in the enhancement and refinement of the technologies he has developed.

Conclusion

Daniel Mufson's contributions to the field of inhalation therapy demonstrate his commitment to innovation and improving patient care. With several patents and a track record of impactful collaborations, he continues to be a key figure in the advancement of medical technologies aimed at enhancing therapeutic effectiveness.

This text is generated by artificial intelligence and may not be accurate.